ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Aspirin Withdrawal Lowers LVAD Bleeding 11/10/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 10, 2025. This episode summarizes 5 key cardiology studies on topics like Coronary function testing and sodium-glucose cotransporter two inhibitors. Key takeaway: Aspirin Withdrawal Lowers LVAD Bleeding.
Article Links:
Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. (Circulation)
Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. (European heart journal)
Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. (European heart journal)
Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. (European heart journal)
Article 5: Clonal Hematopoiesis and Incident Heart Failure. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/
Featured Articles
Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206792
Summary: The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management.
Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206679
Summary: The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices.
Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40796244
Summary: The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population.
Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40796241
Summary: The I.L.I.A.S. A.N.O.C.A. trial investigated the feasibility, safety, and effectiveness of routine ad hoc invasive coronary function testing for diagnosing angina with non-obstructive coronary arteries. This study hypothesized that combining coronary function testing with a disease-specific treatment protocol would significantly improve quality of life compared to standard care. Invasive coronary function testing is known to identify coronary vasomotor disorders in up to 90 percent of patients with angina with non-obstructive coronary arteries. The research aimed to establish a comprehensive diagnostic and treatment pathway for this challenging patient population.
Article 5: Clonal Hematopoiesis and Incident Heart Failure.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206888
Summary: This study investigated the association between specific clonal hematopoiesis of indeterminate potential subtypes and incident heart failure, aiming to identify potential mediating cardiometabolic factors. Researchers sought to determine if particular clonal hematopoiesis driver variants, including less common ones, are linked to heart failure development. This research addresses previous power limitations in examining the association between clonal hematopoiesis and cardiometabolic diseases. By clarifying these associations, the study contributes to a deeper understanding of heart failure pathogenesis and risk stratification.
Transcript
Today’s date is November 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management.
Article number two. Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices.
Article number three. Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population.
Article number four. Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. The I.L.I.A.S. A.N.O.C.A. trial investigated the feasibility, safety, and effectiveness of routine ad hoc invasive coronary function testing for diagnosing angina with non-obstructive coronary arteries. This study hypothesized that combining coronary function testing with a disease-specific treatment protocol would significantly improve quality of life compared to standard care. Invasive coronary function testing is known to identify coronary vasomotor disorders in up to 90 percent of patients with angina with non-obstructive coronary arteries. The research aimed to establish a comprehensive diagnostic and treatment pathway for this challenging patient population.
Article number five. Clonal Hematopoiesis and Incident Heart Failure. This study investigated the association between specific clonal hematopoiesis of indeterminate potential subtypes and incident heart failure, aiming to identify potential mediating cardiometabolic factors. Researchers sought to determine if particular clonal hematopoiesis driver variants, including less common ones, are linked to heart failure development. This research addresses previous power limitations in examining the association between clonal hematopoiesis and cardiometabolic diseases. By clarifying these associations, the study contributes to a deeper understanding of heart failure pathogenesis and risk stratification.
Thank you for listening. Don’t forget to subscribe.
Keywords
Coronary function testing, sodium-glucose cotransporter two inhibitors, diagnostic pathway, quality of life, heart failure, cardiometabolic diseases, Aspirin, thrombotic events, vitamin K antagonists, coronary vasomotor disorders, driver variants, older adults, bleeding reduction, major hemorrhage, Time in Therapeutic Range, extended follow-up, recurrence prevention, major adverse cardiovascular events, Aspirin withdrawal, angina with non-obstructive coronary arteries, Dapagliflozin, atrial fibrillation, left ventricular assist device, HeartMate three, Clonal hematopoiesis of indeterminate potential, primary prevention, risk stratification, catheter ablation.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Aspirin Withdrawal Lowers LVAD Bleeding 11/10/25 first appeared on Cardiology Today.
Article Links:
Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. (Circulation)
Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. (European heart journal)
Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. (European heart journal)
Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. (European heart journal)
Article 5: Clonal Hematopoiesis and Incident Heart Failure. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/
Featured Articles
Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206792
Summary: The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management.
Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206679
Summary: The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices.
Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40796244
Summary: The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population.
Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40796241
Summary: The I.L.I.A.S. A.N.O.C.A. trial investigated the feasibility, safety, and effectiveness of routine ad hoc invasive coronary function testing for diagnosing angina with non-obstructive coronary arteries. This study hypothesized that combining coronary function testing with a disease-specific treatment protocol would significantly improve quality of life compared to standard care. Invasive coronary function testing is known to identify coronary vasomotor disorders in up to 90 percent of patients with angina with non-obstructive coronary arteries. The research aimed to establish a comprehensive diagnostic and treatment pathway for this challenging patient population.
Article 5: Clonal Hematopoiesis and Incident Heart Failure.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206888
Summary: This study investigated the association between specific clonal hematopoiesis of indeterminate potential subtypes and incident heart failure, aiming to identify potential mediating cardiometabolic factors. Researchers sought to determine if particular clonal hematopoiesis driver variants, including less common ones, are linked to heart failure development. This research addresses previous power limitations in examining the association between clonal hematopoiesis and cardiometabolic diseases. By clarifying these associations, the study contributes to a deeper understanding of heart failure pathogenesis and risk stratification.
Transcript
Today’s date is November 10, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management.
Article number two. Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices.
Article number three. Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population.
Article number four. Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. The I.L.I.A.S. A.N.O.C.A. trial investigated the feasibility, safety, and effectiveness of routine ad hoc invasive coronary function testing for diagnosing angina with non-obstructive coronary arteries. This study hypothesized that combining coronary function testing with a disease-specific treatment protocol would significantly improve quality of life compared to standard care. Invasive coronary function testing is known to identify coronary vasomotor disorders in up to 90 percent of patients with angina with non-obstructive coronary arteries. The research aimed to establish a comprehensive diagnostic and treatment pathway for this challenging patient population.
Article number five. Clonal Hematopoiesis and Incident Heart Failure. This study investigated the association between specific clonal hematopoiesis of indeterminate potential subtypes and incident heart failure, aiming to identify potential mediating cardiometabolic factors. Researchers sought to determine if particular clonal hematopoiesis driver variants, including less common ones, are linked to heart failure development. This research addresses previous power limitations in examining the association between clonal hematopoiesis and cardiometabolic diseases. By clarifying these associations, the study contributes to a deeper understanding of heart failure pathogenesis and risk stratification.
Thank you for listening. Don’t forget to subscribe.
Keywords
Coronary function testing, sodium-glucose cotransporter two inhibitors, diagnostic pathway, quality of life, heart failure, cardiometabolic diseases, Aspirin, thrombotic events, vitamin K antagonists, coronary vasomotor disorders, driver variants, older adults, bleeding reduction, major hemorrhage, Time in Therapeutic Range, extended follow-up, recurrence prevention, major adverse cardiovascular events, Aspirin withdrawal, angina with non-obstructive coronary arteries, Dapagliflozin, atrial fibrillation, left ventricular assist device, HeartMate three, Clonal hematopoiesis of indeterminate potential, primary prevention, risk stratification, catheter ablation.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Aspirin Withdrawal Lowers LVAD Bleeding 11/10/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust